Table 13.6a

Immunosuppression Use for Induction, 1994 to 2003

Recipients with Heart-Lung Transplants

	Year of Transplant
	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
Transplants	71	69	39	62	47	51	48	27	32	29
Tx With Immunosuppression Info	68	69	35	59	45	50	48	26	32	27
No Induction Drugs Recorded	70.6%	50.7%	65.7%	71.2%	75.6%	66.0%	47.9%	26.9%	40.6%	55.6%
Drugs	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ALG
ATG/NRATG/NRATS	22.1%	43.5%	28.6%	25.4%	20.0%	16.0%	29.2%	26.9%	15.6%	3.7%
OKT3	7.4%	7.2%	8.6%	6.8%	6.7%	10.0%	6.3%	0.0%	6.3%	3.7%
Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	4.0%	4.2%	11.5%	3.1%	11.1%
Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	4.0%	12.5%	7.7%	15.6%	7.4%
Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.2%	30.8%	18.8%	18.5%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 3, 2004.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.